Discount contracts: Germany's misguided attempt at cost-cutting
This article was originally published in Scrip
Executive Summary
It is extremely easy to be cynical about what are often perceived to be immense profits generated by the research-based pharmaceutical industry. Perhaps in the past it was easy to fall in line with general criticisms, partly because of reciprocally beneficial deals made with between manufacturers and companies or medical professionals. However, the introduction of self regulation and codes of practice have largely eradicated these agreements. Increasingly, profits are being ploughed back into research and development as the emergence of new chemical entities dries up.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.